icon bookmark-bicon bookmarkicon cameraicon checkicon chevron downicon chevron lefticon chevron righticon chevron upicon closeicon v-compressicon downloadicon editicon v-expandicon fbicon fileicon filtericon flag ruicon full chevron downicon full chevron lefticon full chevron righticon full chevron upicon gpicon insicon mailicon moveicon-musicicon mutedicon nomutedicon okicon v-pauseicon v-playicon searchicon shareicon sign inicon sign upicon stepbackicon stepforicon swipe downicon tagicon tagsicon tgicon trashicon twicon vkicon yticon wticon fm

Is Bayer off the hook after coughing up $10 BILLION to settle Monsanto weedkiller lawsuits? RT’s Boom Bust finds out

Is Bayer off the hook after coughing up $10 BILLION to settle Monsanto weedkiller lawsuits? RT’s Boom Bust finds out
Bayer, the company behind the controversial Roundup weedkiller after its takeover of Monsanto, has recently reached an agreement to put an end to most of the current and possible future lawsuits for more than $10 billion.

The settlement covers around 75 percent of current Roundup litigation, involving approximately 125,000 filed and unfiled claims overall. The most interesting part of the announcement is the company’s pledge to finance a scientific panel that is set to take a closer look at the weedkiller and its key ingredient, glyphosate, which is considered to be potentially carcinogenic.

“It they [scientists] find that glyphosate... can cause cancer, then they’re gonna face potentially more lawsuits,” Mollye Barrows of America’s Lawyer told Boom Bust. On the other hand, if the research concludes that there is no cancer risk, then people will not be able to sue the pharmaceutical giant anymore, she added.

The problem with such a study is that it can be biased and can be pushed to bring the results its sponsors need, the contributor noted.

“As we’ve seen in other cases, sometimes that data is manipulated and they put forward what they want. Not to mention that during these four years these products will stay on the shelf, so that’s good news for Bayer,” she said.

For more stories on economy & finance visit RT's business section

Dear readers and commenters,

We have implemented a new engine for our comment section. We hope the transition goes smoothly for all of you. Unfortunately, the comments made before the change have been lost due to a technical problem. We are working on restoring them, and hoping to see you fill up the comment section with new ones. You should still be able to log in to comment using your social-media profiles, but if you signed up under an RT profile before, you are invited to create a new profile with the new commenting system.

Sorry for the inconvenience, and looking forward to your future comments,

RT Team.